Hepatitis D cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
(Category) |
m (Bot: Removing from Primary care) |
||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Hepatitis|D]] | [[Category:Hepatitis|D]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
Latest revision as of 22:06, 29 July 2020
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis D cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatitis D cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Considering that patients who develop symptomatic hepatitis D may progress into cirrhosis, liver failure and hepatocellular carcinoma, research for an adequate therapeutic regimen and for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective.